• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Lyell Immunopharma Inc.

    2/14/22 4:10:57 PM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LYEL alert in real time by email
    SC 13G 1 d279280dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No.     )*

     

     

    LYELL IMMUNOPHARMA, INC.

    (Name of Issuer)

    COMMON STOCK, $0.0001 PAR VALUE

    (Title of Class of Securities)

    55083R104

    (CUSIP Number)

    DECEMBER 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐

    Rule 13d-1(b)

    ☐

    Rule 13d-1(c)

    ☑

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 55083R104    13G    Page 2 of 8 Pages

     

      1.    

      NAMES OF REPORTING PERSONS

     

      I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

      Newton (PTC) Limited

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☑

     

      3.  

      SEC USE ONLY

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      British Virgin Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

      SOLE VOTING POWER

     

      15,093,969

       6.  

      SHARED VOTING POWER

     

      0

       7.  

      SOLE DISPOSITIVE POWER

     

      15,093,969

       8.  

      SHARED DISPOSITIVE POWER

     

      0

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      15,093,969

    10.  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      6.28%

    12.  

      TYPE OF REPORTING PERSON

     

      CO


    CUSIP No. 55083R104    13G    Page 3 of 8 Pages

     

      1.    

      NAMES OF REPORTING PERSONS

     

      I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

      Orland Properties Limited

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☑

     

      3.  

      SEC USE ONLY

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      British Virgin Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

      SOLE VOTING POWER

     

      15,093,969

       6.  

      SHARED VOTING POWER

     

      0

       7.  

      SOLE DISPOSITIVE POWER

     

      15,093,969

       8.  

      SHARED DISPOSITIVE POWER

     

      0

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      15,093,969

    10.  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      6.28%

    12.  

      TYPE OF REPORTING PERSON

     

      CO


    CUSIP No. 55083R104    13G    Page 4 of 8 Pages

     

      1.    

      NAMES OF REPORTING PERSONS

     

      I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

      Gemini GP Limited

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☑

     

      3.  

      SEC USE ONLY

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Cayman Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

      SOLE VOTING POWER

     

      15,093,969

       6.  

      SHARED VOTING POWER

     

      0

       7.  

      SOLE DISPOSITIVE POWER

     

      15,093,969

       8.  

      SHARED DISPOSITIVE POWER

     

      0

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      15,093,969

    10.  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      6.28%

    12.  

      TYPE OF REPORTING PERSON

     

      CO


    CUSIP No. 55083R104    13G    Page 5 of 8 Pages

     

      1.    

      NAMES OF REPORTING PERSONS

     

      I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

      Gemini Investments, L.P.

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☑

     

      3.  

      SEC USE ONLY

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Cayman Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

      SOLE VOTING POWER

     

      15,093,969

       6.  

      SHARED VOTING POWER

     

      0

       7.  

      SOLE DISPOSITIVE POWER

     

      15,093,969

       8.  

      SHARED DISPOSITIVE POWER

     

      0

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      15,093,969

    10.  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      6.28%

    12.  

      TYPE OF REPORTING PERSON

     

      PN


    CUSIP No. 55083R104    13G    Page 6 of 8 Pages

     

    Item 1(a).

    Name of Issuer:

    Lyell Immunopharma, Inc.

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    201 Haskins Way

    South San Francisco, California

     

    Item 2.

    (a) – (c)        Name of Persons Filing; Address; Citizenship

    This statement on Schedule 13(G) is being filed jointly by the following persons, collectively, the “Reporting Persons”:

     

      i.

    Newton (PTC) Limited

    Address: c/o Trident Trust Company (B.V.I.) Limited, Trident Chambers, P.O. Box 146, Road Town, Tortola, British Virgin Islands

    Citizenship: British Virgin Islands

     

      ii.

    Orland Properties Limited

    Address: c/o Trident Trust Company (B.V.I.) Limited, Trident Chambers, P.O. Box 146, Road Town, Tortola, British Virgin Islands

    Citizenship: British Virgin Islands

     

      iii.

    Gemini GP Limited

    Address: c/o Trident Trust Company (Cayman) Limited, One Capital Place, P.O. Box 847, Grand Cayman, KY1-1103, Cayman Islands

    Citizenship: Cayman Islands

     

      iv.

    Gemini Investments, L.P.

    Address: c/o Trident Trust Company (Cayman) Limited, One Capital Place, P.O. Box 847, Grand Cayman, KY1-1103, Cayman Islands

    Citizenship: Cayman Islands

     

    Item 2(d).

    Title of Class of Securities:

    Common Stock, $0.0001 par value (“Common Stock”)

     

    Item 2(e).

    CUSIP Number:

    55083R104

     

    Item 3.

    Not applicable.


    CUSIP No. 55083R104    13G    Page 7 of 8 Pages

     

    Item 4.

    Ownership.

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on 240,471,497 shares of Common Stock outstanding as of November 12, 2021, as reported by the Issuer in its 10-Q filed with the Securities and Exchange Commission on November 12, 2021.

    Gemini GP Limited is the general partner of Gemini Investments, L.P., and as such, may be deemed to beneficially own the shares held directly by Gemini Investments, L.P.

    Orland Properties Limited wholly owns Gemini GP Limited, and as such, may be deemed to beneficially own the shares beneficially owned by Gemini GP Limited.

    Newton (PTC) Limited wholly owns Orland Properties Limited, and as such, may be deemed to beneficially own the shares beneficially owned by Orland Properties Limited.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ ].

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item

    10. Certification.

    Not applicable.


    CUSIP No. 55083R104    13G    Page 8 of 8 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 14, 2022

     

    NEWTON (PTC) LIMITED
    /s/ David Muir
    Name: David Muir
    Title: President

     

    ORLAND PROPERTIES LIMITED
    //s/ David Muir
    Name: David Muir
    Title: President

     

    GEMINI GP LIMITED
    /s/ David Muir
    Name: David Muir
    Title: President

     

    GEMINI INVESTMENTS, L.P.

    By: Gemini GP Limited, its General Partner

    /s/ David Muir
    Name: David Muir
    Title: President
    Get the next $LYEL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LYEL

    DatePrice TargetRatingAnalyst
    3/9/2026$34.00Mkt Outperform
    Citizens
    12/9/2025$45.00Neutral → Buy
    H.C. Wainwright
    10/30/2024$6.00 → $1.00Buy → Underperform
    BofA Securities
    6/27/2024$6.00 → $1.00Buy → Neutral
    H.C. Wainwright
    8/28/2023$15.00 → $5.00Overweight → Neutral
    JP Morgan
    11/14/2022$15.00 → $7.00Overweight → Equal-Weight
    Morgan Stanley
    11/11/2022$13.00 → $7.00Buy → Neutral
    Goldman
    10/17/2022$12.00Buy
    H.C. Wainwright
    More analyst ratings

    $LYEL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results

    Patient dosing has commenced in first-of-its-kind Phase 3 head-to-head CAR T-cell 2L randomized controlled clinical trial (PiNACLE-H2H) in patients with large B-cell lymphoma, and the 3L+ pivotal trial (PiNACLE) evaluating ronde-cel is ongoingPhase 1 trial is ongoing for LYL273, an enhanced GCC-targeted CAR T-cell candidate for metastatic colorectal cancer; seven new patients treated without dose-limiting toxicity and including dose escalation to Dose Level 3Smital Shah was appointed Chief Financial and Business Officer in March 2026Second $50 million tranche of $100 million equity private placement closed in March 2026 after achievement of clinical milestone for ronde-celCash of approximate

    3/12/26 4:05:00 PM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer

    Closing of additional $50 million tranche of $100 million equity private placement after achievement of clinical milestone for rondecabtagene autoleucelSmital Shah appointed Chief Financial and Business Officer SOUTH SAN FRANCISCO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced it has closed the sale of an additional $50 million of shares of its common stock to investors from its July 2025 equity private placement of up to $100 million, following achievement of a clinical milestone within its Pi

    3/9/26 8:00:00 AM ET
    $LYEL
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lyell Immunopharma Announces Participation in March Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will present and participate in the following investor conferences: TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, in Boston, Massachusetts; presentation at 9:10am Eastern TimeLeerink Annual Global Healthcare Conference on Monday, March 9, 2026, in Miami, Florida; fireside chat at 10:00am Eastern TimeCitizens Life Science Conference on Tuesday, March 10, 2026, in Miami,

    2/23/26 8:00:00 AM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LYEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Fin. and Bus. Officer Shah Smital

    4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)

    3/16/26 7:26:24 PM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Shah Smital

    3 - Lyell Immunopharma, Inc. (0001806952) (Issuer)

    3/16/26 7:24:50 PM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Arch Venture Partners Ix, Llc bought $12,499,985 worth of shares (488,090 units at $25.61) (SEC Form 4)

    4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)

    3/9/26 4:36:20 PM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LYEL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Arch Venture Partners Ix, Llc bought $12,499,985 worth of shares (488,090 units at $25.61) (SEC Form 4)

    4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)

    3/9/26 4:36:20 PM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Arch Venture Fund Xiii, L.P. bought $12,499,985 worth of shares (488,090 units at $25.61) (SEC Form 4)

    4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)

    3/9/26 4:34:54 PM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Brawley Otis W bought $19,958 worth of shares (35,640 units at $0.56) (SEC Form 4)

    4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)

    4/2/25 3:46:01 PM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LYEL
    SEC Filings

    View All

    SEC Form S-8 filed by Lyell Immunopharma Inc.

    S-8 - Lyell Immunopharma, Inc. (0001806952) (Filer)

    3/12/26 4:50:15 PM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Lyell Immunopharma Inc.

    10-K - Lyell Immunopharma, Inc. (0001806952) (Filer)

    3/12/26 4:16:26 PM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lyell Immunopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Lyell Immunopharma, Inc. (0001806952) (Filer)

    3/12/26 4:12:21 PM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LYEL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citizens initiated coverage on Lyell Immunopharma with a new price target

    Citizens initiated coverage of Lyell Immunopharma with a rating of Mkt Outperform and set a new price target of $34.00

    3/9/26 9:07:38 AM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lyell Immunopharma upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Lyell Immunopharma from Neutral to Buy and set a new price target of $45.00

    12/9/25 8:34:46 AM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lyell Immunopharma downgraded by BofA Securities with a new price target

    BofA Securities downgraded Lyell Immunopharma from Buy to Underperform and set a new price target of $1.00 from $6.00 previously

    10/30/24 6:29:00 AM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LYEL
    Financials

    Live finance-specific insights

    View All

    Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition

    93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell lymphoma in the 3L+ setting83% overall response and 61% complete response rates in cohort comprised predominantly of patients with primary refractory large B-cell lymphoma in the 2L settingManageable safety profile appropriate for outpatient administration; no high-grade CRS and ≤ 5% of patients with Grade ≥ 3 ICANS following dexamethasone prophylaxisLyell management will host an investor webcast with presenting author and ronde-cel investigator Sarah M. Larson, MD, Associate Professor at the David Geffen School of Medicine, University of California, Los Angel

    12/7/25 4:30:00 PM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer

    LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic colorectal cancer enrolled in an ongoing U.S. Phase 1 clinical trialLYL273 is a GCC-targeted CAR T-cell product candidate armed with enhancements designed to improve CAR T-cell expansion and cancer cell killingLyell management will host an investor webcast at 8:30 AM ET today SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a late-stage clinical company advancing next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with

    11/10/25 7:30:00 AM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma

    LYL314 demonstrated robust clinical responses, with an 88% overall response rate and a 72% complete response rate in patients treated in the third- or later-line setting (N = 25)71% of patients with complete response remained in complete response at ≥ 6 monthsManageable safety profile appropriate for outpatient administration with no Grade ≥ 3 cytokine release syndrome and low rates of Grade ≥ 3 ICANS with rapid resolutionPivotal single-arm PiNACLE trial is underway in CAR T-naïve patients with large B-cell lymphoma treated in the third- or later-line settingLyell to host an investor webcast at 8:00 AM ET today SOUTH SAN FRANCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Lyell Immunoph

    6/17/25 6:30:00 AM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LYEL
    Leadership Updates

    Live Leadership Updates

    View All

    Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results

    Patient dosing has commenced in first-of-its-kind Phase 3 head-to-head CAR T-cell 2L randomized controlled clinical trial (PiNACLE-H2H) in patients with large B-cell lymphoma, and the 3L+ pivotal trial (PiNACLE) evaluating ronde-cel is ongoingPhase 1 trial is ongoing for LYL273, an enhanced GCC-targeted CAR T-cell candidate for metastatic colorectal cancer; seven new patients treated without dose-limiting toxicity and including dose escalation to Dose Level 3Smital Shah was appointed Chief Financial and Business Officer in March 2026Second $50 million tranche of $100 million equity private placement closed in March 2026 after achievement of clinical milestone for ronde-celCash of approximate

    3/12/26 4:05:00 PM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments

    Mark J. Bachleda, PharmD, MBA appointed as independent member of the Board of DirectorsDavid Shook, MD appointed as Chief Medical Officer, Mark Meltz, JD as General Counsel and Corporate Secretary, and Jarrad Aguirre, MD, MBA as Senior Vice-President of Medical Affairs SOUTH SAN FRANCISCO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced the appointment of Mark J. Bachleda, PharmD, MBA as an independent member of the Board of Directors, David Shook, MD as Chief Medical Officer, and Mark Meltz, JD as General Counsel and Corporate

    6/9/25 4:05:00 PM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023

    Cash, cash equivalents and marketable securities of $632.7 million as of June 30, 2023 support advancing multiple product candidates through key clinical milestonesRemain on track for initial clinical data from two lead product candidates in 2024Further strengthened executive leadership with appointment of Matt Lang, J.D., as Chief Business Officer SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today reported financial results and business highlights for the second quarter ended June 30, 2023. "Lyell continues

    8/8/23 4:05:00 PM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LYEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Lyell Immunopharma Inc.

    SC 13G/A - Lyell Immunopharma, Inc. (0001806952) (Subject)

    11/12/24 4:04:21 PM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lyell Immunopharma Inc.

    SC 13G/A - Lyell Immunopharma, Inc. (0001806952) (Subject)

    11/4/24 1:30:41 PM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Lyell Immunopharma Inc.

    SC 13G - Lyell Immunopharma, Inc. (0001806952) (Subject)

    10/31/24 6:00:17 PM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care